SS-31 vs Tesamorelin
SS-31 and Tesamorelin are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: SS-31 is mitochondria-targeting aromatic-cationic tetrapeptide (cardiolipin-binding), while Tesamorelin is full-length 44-residue ghrh analogue with trans-3-hexenoic acid modification — different molecular classes with different handling consequences; their leading degradation routes differ (adsorptive loss to plasticware from the cationic charge for SS-31, aggregation at air–liquid interfaces from agitation for Tesamorelin), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
SS-31 — origin
SS-31 (Elamipretide) is a Szeto-Schiller aromatic-cationic tetrapeptide (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane and binds cardiolipin, the lipid unique to that membrane. Its structure is the reason it is studied specifically at the mitochondrion rather than as a general antioxidant.
Tesamorelin — origin
Tesamorelin is the complete 44-amino-acid sequence of human growth hormone-releasing hormone with a trans-3-hexenoic acid group attached at the N-terminus. That modification exists for one reason: native GHRH is cleaved almost immediately by dipeptidyl peptidase-4 at the N-terminal end, and the hexenoyl group blocks that cleavage.
SS-31 research themes
Studied for selective association with cardiolipin in the inner mitochondrial membrane, the basis of its mitochondrial targeting.
Examined for effects on mitochondrial energy production in research models of mitochondrial dysfunction.
Investigated around reactive-oxygen-species handling at the mitochondrion.
Tesamorelin research themes
Full-length GHRH activity with DPP-4 resistance conferred by the N-terminal modification.
The most distinctive endpoint in its research literature.
Studied for effects on endogenous GH secretion patterns rather than direct GH substitution.
Investigated alongside body-composition endpoints in metabolic research.
SS-31 handling
- Reach room temperature before opening.
- Use low-bind labware and buffers at low working concentrations to limit adsorption of the cationic peptide.
- Aliquot and refrigerate.
Tesamorelin handling
- Allow several minutes for dissolution; do not accelerate with agitation or heat.
- Swirl gently — long chains aggregate at interfaces.
- Do not freeze reconstituted solution.
Both third-party tested
Every Popular Peptides batch of SS-31 and Tesamorelin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
SS-31 reference
Related comparisons
SS-31 and Tesamorelin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.